Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis

被引：0
作者：
Feiqiong Gao
Jiawei Zhang
Jianlai Hu
Liming Lin
Yang Xu
机构：
[1] The Second Affiliated Hospital of Zhejiang University School of Medicine,Department of Hematology
[2] The Second Affiliated Hospital of Zhejiang University School of Medicine,Department of Prosthodontics
[3] Zhejiang University,Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute
[4] the First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases
来源：
Annals of Hematology | 2021年 / 100卷
关键词：
Post-transplant cyclophosphamide; Antithymocyte globulin; Graft-versus-host disease; Allogeneic hematopoietic stem cell transplantations; Prophylaxis; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Graft-versus-host disease (GVHD) prophylaxis based on post-transplant cyclophosphamide (PTCy) or antithymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantations (allo-HCT). The differential impacts of PTCy and ATG on transplantation outcomes are not well characterized. Here we report a meta-analysis of PTCy versus ATG in allo-HCT. Ten studies were eligible, and a total of 1871 patients were included. The incidence of II-IV aGVHD, III-IV aGVHD, and NRM were significantly lower in PTCy arm (HR = 0.63, 95% CI 0.45–0.89; HR = 0.35, 95% CI 0.16–0.77; HR = 0.59, 95% CI 0.48–0.73). PTCy was associated with a better OS and PFS (HR = 0.62, 95% CI = 0.53–0.73; HR = 0.76, 95% CI 0.62–0.93). The relapse rate and cGVHD incidence were not significantly different between PTCy and ATG (HR = 0.85, 95% CI 0.68–1.07; HR = 0.65, 95% CI 0.38–1.12). Thus, compared with ATG, PTCy has a better aGVHD control and OS benefit, without increasing relapse risk, which needs further validation in prospective randomized trials.
引用
收藏
页码：529 / 540
页数：11
相关论文
共 489 条
[1]  
McCurdy SR(2017)Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide Haematologica 102 391-400
[2]  
Kasamon YL(2018)Biology-driven developments in the therapy of acute graft-versus-host disease Hematology Am Soc Hematol Educ Program 2018 236-241
[3]  
Kanakry CG(2016)Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations Immunotherapy 8 435-447
[4]  
Bolanos-Meade J(2018)Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis Expert Rev Hematol 12 47-60
[5]  
Tsai HL(2018)Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation Bone Marrow Transplant 54 601-606
[6]  
Showel MM(2013)Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation Biol Blood Marrow Transplant 19 1430-1438
[7]  
Kanakry JA(2019)Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis Jpn J Clin Oncol 49 924-931
[8]  
Symons HJ(2019)Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application Bone Marrow Transplant 55 40-47
[9]  
Gojo I(2019)Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis Bone Marrow Transplant 54 1094-1106
[10]  
Smith BD(2012)Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation Biol Blood Marrow Transplant 18 1835-1844
12345678910